Claims

WHAT IS CLAIMED IS:

1. A compound having the structure:



or a pharmaceutically acceptable salt, prodrug, tautomer or isomer thereof.

2. A pharmaceutical composition comprising the compound of claim 1 and at least one pharmaceutically acceptable carrier.

3. A method for treating or preventing a thrombolytic condition in a subject, the method comprising administering to the subject a compound having the structure:



or a pharmaceutically acceptable salt, tautomer, prodrug or isomer thereof.

4. The method of claim 3 wherein the thrombolytic condition is selected from the group consisting of myocardial infarction, stroke, amaurosis fugax, aortic stenosis, cardiac stenosis, coronary stenosis and pulmonary stenosis.

5. A method for substantially inhibiting thrombus formation in a subject, the method comprising administering to the subject a compound having the structure:



or a pharmaceutically acceptable salt, tautomer, prodrug or isomer thereof.

6. A method for substantially inhibiting an enzyme involved in the coagulation cascade, the method comprising administering to a subject a compound having the structure:



or a pharmaceutically acceptable salt, tautomer, prodrug, or isomer thereof.

7. The method of claim 6 wherein the enzyme is a serine protease.

8. The method of claim 7 wherein the serine protease is a part of the TF/VIIa complex.

9. A composition comprising the compound of claim 1 or a pharmaceutically acceptable salt, tautomer, prodrug or isomer thereof and a thrombolytic agent.

10. The composition of claim 9 wherein the thrombolytic agent is selected from the group consisting of anti-platelet agents, anticoagulation agents and cardiovascular agents.

11. The composition of claim 10 wherein the thrombolytic agent is an anti-platelet agent.

12. The composition of claim 11 wherein the anti-platelet agent is selected from the group consisting of a salicylate compound, ticlopidine, clopidrogel, and a GP IIa/IIIa inhibitor.

13. The composition of claim 12 wherein the anti-platelet agent is a salicylate compound.

14. The composition of claim 13 wherein the salicylate compound is aspirin.

15. A method for the treatment or prevention of a thrombolytic condition in a subject, the method comprising administering to the subject the compound of claim 1 or a pharmaceutically acceptable salt, prodrug, tautomer, or isomer thereof and a thrombolytic agent.

16. The method of claim 15 wherein the thrombolytic agent is selected from the group consisting of anti-platelet agents, anticoagulation agents and cardiovascular agents.

17. The method of claim 16 wherein the thrombolytic agent is an anti-platelet agent.

18. The method of claim 17 wherein the anti-platelet agent is selected from the group consisting of a salicylate compound, ticlopidine, clopidrogel, and a GP IIa/IIIa inhibitor.

19. The method of claim 18 wherein the anti-platelet agent is a salicylate compound.

20. The method of claim 19 wherein the salicylate compound is aspirin.

21. The method of claim 15 wherein the thrombolytic condition is selected from the group consisting of myocardial infarction, stroke, amaurosis fugax, aortic stenosis, cardiac stenosis, coronary stenosis and pulmonary stenosis.

22. The method of claim 15 wherein the compound of claim 1 and the thrombolytic agent are administered in a substantially simultaneous manner.

23. The method of claim 15 wherein the compound of claim 1 and the thrombolytic agent are administered sequentially.

24. An extract of a *Dysidea* sponge comprising a compound having the structure:



or a pharmaceutically acceptable salt, prodrug, tautomer or isomer thereof.